Poulsen Bradley E, Rath Arianna, Deber Charles M
Division of Molecular Structure and Function, Research Institute, Hospital for Sick Children, Toronto, Ontario M5G 1X8.
J Biol Chem. 2009 Apr 10;284(15):9870-5. doi: 10.1074/jbc.M900182200. Epub 2009 Feb 18.
Multidrug transporters such as the small multidrug resistance (SMR) family of bacterial integral membrane proteins are capable of conferring clinically significant resistance to a variety of common therapeutics. As antiporter proteins of approximately 100 amino acids, SMRs must self-assemble into homo-oligomeric structures for efflux of drug molecules. Oligomerization centered at transmembrane helix four (TM4) has been implicated in SMR assembly, but the full complement of residues required to mediate its self-interaction remains to be characterized. Here, we use Hsmr, the 110-residue SMR family member of the archaebacterium Halobacterium salinarum, to determine the TM4 residue motif required to mediate drug resistance and SMR self-association. Twelve single point mutants that scan the central portion of the TM4 helix (residues 85-104) were constructed and were tested for their ability to confer resistance to the cytotoxic compound ethidium bromide. Six residues were found to be individually essential for drug resistance activity (Gly(90), Leu(91), Leu(93), Ile(94), Gly(97), and Val(98)), defining a minimum activity motif of (90)GLXLIXXGV(98) within TM4. When the propensity of these mutants to dimerize on SDS-PAGE was examined, replacements of all but Ile resulted in approximately 2-fold reduction of dimerization versus the wild-type antiporter. Our work defines a minimum activity motif of (90)GLXLIXXGV(98) within TM4 and suggests that this sequence mediates TM4-based SMR dimerization along a single helix surface, stabilized by a small residue heptad repeat sequence. These TM4-TM4 interactions likely constitute the highest affinity locus for disruption of SMR function by directly targeting its self-assembly mechanism.
多药转运蛋白,如细菌整合膜蛋白的小多药耐药性(SMR)家族,能够对多种常见治疗药物产生临床上显著的耐药性。作为约100个氨基酸的反向转运蛋白,SMR必须自组装成同源寡聚体结构才能排出药物分子。以跨膜螺旋4(TM4)为中心的寡聚化与SMR组装有关,但介导其自身相互作用所需的完整残基仍有待确定。在这里,我们使用嗜盐古菌盐生盐杆菌的110个残基的SMR家族成员Hsmr,来确定介导耐药性和SMR自缔合所需的TM4残基基序。构建了12个扫描TM4螺旋中心部分(残基85 - 104)的单点突变体,并测试了它们赋予对细胞毒性化合物溴化乙锭耐药性的能力。发现6个残基对于耐药活性是单独必需的(Gly(90)、Leu(91)、Leu(93)、Ile(94)、Gly(97)和Val(98)),在TM4内定义了一个最小活性基序(90)GLXLIXXGV(98)。当检查这些突变体在SDS - PAGE上二聚化的倾向时,除了Ile之外的所有取代导致二聚化相对于野生型反向转运蛋白降低约2倍。我们的工作在TM4内定义了一个最小活性基序(90)GLXLIXXGV(98),并表明该序列沿着单个螺旋表面介导基于TM4的SMR二聚化,由一个小残基七肽重复序列稳定。这些TM4 - TM4相互作用可能通过直接靶向其自组装机制构成破坏SMR功能的最高亲和力位点。